Granite Point Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Granite Point Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-176,456	Closed	-$295K	–	110
2022 Q3	$295K	Sell	176,456 -1	-0%	-$2	0.12%	79
2022 Q2	$489K	Hold	176,457	–	–	0.12%	72
2022 Q1	$590K	Buy	176,457 +120,000	+213%	+$621K	0.12%	93
2021 Q4	$347K	Buy	56,457 +9,668	+21%	+$101K	0.06%	113
2021 Q3	$649K	Buy	+46,789	New	+$652K	0.05%	112
2021 Q1	–	Sell	-128,440	Closed	-$3.72M	–	206
2020 Q4	$3.72M	Sell	128,440 -18,227	-12%	-$526K	0.19%	48
2020 Q3	$5.52M	Hold	146,667	–	–	0.3%	44
2020 Q2	$4.88M	Buy	+146,667	New	+$6.36M	0.25%	48

Other funds holding SLNO

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Clayton Partners Berkeley, California $152M AUM 42.38% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Granite Point Capital Management's SLNO Position: Q4 2022 in Review

Granite Point Capital Management sold out of Soleno Therapeutics (SLNO) in Q4 2022, closing a stake of 176,456 shares — an estimated $295K sold.

Granite Point Capital Management first reported a position in SLNO in Q2 2020 and held it in 8 quarters. The position peaked at $5.52M in Q3 2020. 26 funds tracked by Wall St. Rank hold SLNO as of Q4 2022.

Granite Point Capital Management reported no remaining Soleno Therapeutics position as of Q4 2022 after selling out during the quarter.
Granite Point Capital Management sold 176,456 Soleno Therapeutics shares in Q4 2022, an estimated $295K.
Granite Point Capital Management first reported a position in Soleno Therapeutics in Q2 2020 and held it in 8 quarters.
Granite Point Capital Management's Soleno Therapeutics position peaked at $5.52M in Q3 2020.
26 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2022.

Based on Granite Point Capital Management's 13F filing for Q4 2022, filed 7 Feb 2023.